WO2023208993 - BIOMARKERS OF DIABETIC NEPHROPATHY
National phase entry:
Publication Number
WO/2023/208993
Publication Date
02.11.2023
International Application No.
PCT/EP2023/060911
International Filing Date
26.04.2023
Title **
[English]
BIOMARKERS OF DIABETIC NEPHROPATHY
[French]
BIOMARQUEURS DE NÉPHROPATHIE DIABÉTIQUE
Applicants **
RANDOX LABORATORIES LTD
55 Diamond Road
Ardmore, Crumlin
Antrim BT294QY, GB
Inventors
RUDDOCK, Mark
Randox Laboratories ltd
Ardmore
55 Diamond Road
Crumlin Antrim BT294QY, GB
JOANNE, Watt
Randox Laboratories
Ardmore
55 Diamond Road
Crumlin Antrim BT294QY, GB
FITZGERALD, Peter
Randox Laboratories
Ardmore
55 Diamond Road
Crumlin Antrim BT294QY, GB
LAMONT, John
Randox Laboratories
Ardmore
55 Diamond Road
Crumlin Antrim BT294QY, GB
Priority Data
2206257.4
29.04.2022
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 988 | |
| EPO | Filing, Examination | 4675 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3310 |
Total: 10142 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods of diagnosing type 2 diabetes mellitus and diabetic nephropathy are described that make use of a combination of biomarkers chosen from sTNFR1, H-FABP, midkine, cystatin C, sTNFR2 and L-FABP.[French]
L'invention concerne des méthodes de diagnostic du diabète sucré de type 2 et de la néphropathie diabétique qui utilisent une combinaison de biomarqueurs choisis parmi sTNFR1, H-FABP, midkine, cystatine C, sTNFR2 et L-FABP.